GSK outlines RSV and oncology focus, shares track sector peers on NYSE

GSK sets out a clear medium-term focus on vaccines and oncology, while consensus still points to modest upside for the shares versus big pharma peers such as Pfizer and Sanofi.

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 14:01.

GSK (GB0009252882) remains a diversified big pharma player on the NYSE, with investors watching how its vaccines and specialty medicines strategy translates into earnings over the next few years. According to consensus data summarized by MarketBeat, analysts still see moderate upside for the shares versus current levels.MarketBeat overview for GSK

What analysts say on GSK

Analyst opinion on GSK is mixed but tilted toward neutral, with a cluster of Hold ratings and a smaller group of Buy recommendations, as aggregated by MarketBeat.MarketBeat analyst ratings for GSK The average 12?month price target in that sample still sits modestly above the recent closing price of 52.49 US dollars on the NYSE for 2026-06-26.

That leaves GSK trading at a discount to some large pharma peers such as Pfizer and Sanofi on classic valuation metrics like forward earnings multiples, according to comparative screens cited by MarketBeat.MarketBeat peer comparison for GSK For retail investors, the picture is one of cautious expectations rather than aggressive growth assumptions priced into the stock.

Long-term strategy and pipeline focus

Strategically, GSK continues to emphasize vaccines, HIV and oncology as the core engines for future growth, as reiterated in its latest investor materials.GSK investor information Key products include the RSV vaccine Arexvy, shingles vaccine Shingrix and HIV treatments marketed through the ViiV Healthcare joint venture, alongside an expanding oncology pipeline.

In recent quarters GSK has highlighted the contribution of vaccines to group sales, underlining a strategy that leans more heavily on immunization than competitors such as Pfizer and Sanofi in some categories.Reuters coverage of GSK vaccine strategy Management has also pointed to cost discipline and portfolio simplification as tools to protect margins through the investment cycle.

The products behind GSK

GSK generates a large share of its revenue from vaccines such as Shingrix, which protects against shingles, and the RSV vaccine Arexvy for older adults, alongside respiratory brands like Trelegy in chronic obstructive pulmonary disease. The group also participates in the HIV market through ViiV Healthcare and is investing in oncology assets targeting multiple tumor types.

Where the GSK shares trade today

The GSK shares (GB0009252882) last closed on 2026-06-26 on the NYSE at 52.49 US dollars.

Key data on the GSK shares

• Company: GSK plc
• ISIN: GB0009252882
• WKN: 940561
• Ticker: GSK
• Trading venue: NYSE
• Price (as of 2026-06-26, 21:59): 52.49 USD
• Market cap: 108.5 billion USD (as of 2026-06-26)
• Sector / industry: Pharmaceuticals & Biotechnology
• Index membership: FTSE 100
• Next earnings date: 2026-07-31

This article is for informational purposes only and does not constitute investment advice, an offer or a solicitation to buy or sell any securities. All data were carefully researched but carry no guarantee. Investors should make their own decisions and, where appropriate, consult a qualified financial advisor.